These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
396 related articles for article (PubMed ID: 25446664)
21. Synergistic effect of MEK inhibitor and metformin combination in low grade serous ovarian cancer. Mert I; Chhina J; Allo G; Dai J; Seward S; Carey MS; Llaurado M; Giri S; Rattan R; Munkarah AR Gynecol Oncol; 2017 Aug; 146(2):319-326. PubMed ID: 28545687 [TBL] [Abstract][Full Text] [Related]
22. Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway. Chang MC; Chen CA; Hsieh CY; Lee CN; Su YN; Hu YH; Cheng WF Biochem J; 2009 Dec; 424(3):449-58. PubMed ID: 19747165 [TBL] [Abstract][Full Text] [Related]
23. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer. Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434 [TBL] [Abstract][Full Text] [Related]
24. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Rosanò L; Di Castro V; Spinella F; Nicotra MR; Natali PG; Bagnato A Mol Cancer Ther; 2007 Jul; 6(7):2003-11. PubMed ID: 17620430 [TBL] [Abstract][Full Text] [Related]
25. Metformin targets ovarian cancer stem cells in vitro and in vivo. Shank JJ; Yang K; Ghannam J; Cabrera L; Johnston CJ; Reynolds RK; Buckanovich RJ Gynecol Oncol; 2012 Nov; 127(2):390-7. PubMed ID: 22864111 [TBL] [Abstract][Full Text] [Related]
26. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Yamamura S; Matsumura N; Mandai M; Huang Z; Oura T; Baba T; Hamanishi J; Yamaguchi K; Kang HS; Okamoto T; Abiko K; Mori S; Murphy SK; Konishi I Int J Cancer; 2012 Jan; 130(1):20-8. PubMed ID: 21503873 [TBL] [Abstract][Full Text] [Related]
27. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter? Modesitt SC; Parsons SJ Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975 [TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Cooper AL; Greenberg VL; Lancaster PS; van Nagell JR; Zimmer SG; Modesitt SC Gynecol Oncol; 2007 Mar; 104(3):596-601. PubMed ID: 17049973 [TBL] [Abstract][Full Text] [Related]
29. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models. Zi FM; He JS; Li Y; Wu C; Yang L; Yang Y; Wang LJ; He DH; Zhao Y; Wu WJ; Zheng GF; Han XY; Huang H; Yi Q; Cai Z Cancer Lett; 2015 Jan; 356(2 Pt B):443-53. PubMed ID: 25305450 [TBL] [Abstract][Full Text] [Related]
30. Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. Litchfield LM; Mukherjee A; Eckert MA; Johnson A; Mills KA; Pan S; Shridhar V; Lengyel E; Romero IL Oncotarget; 2015 Sep; 6(27):23548-60. PubMed ID: 26172303 [TBL] [Abstract][Full Text] [Related]
31. Antitumor and normal cell protective effect of PKC412 in the athymic mouse model of ovarian cancer. Kim M; Park IY; Lim J; Kim Y; Han KT; Chung WH; Han K Ann Clin Lab Sci; 2006; 36(4):455-60. PubMed ID: 17127735 [TBL] [Abstract][Full Text] [Related]
32. Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results. Paine GD; Taylor CW; Lopez MH; Johnson CS; Capizzi RL Semin Oncol; 1996 Aug; 23(4 Suppl 8):35-9. PubMed ID: 8783664 [TBL] [Abstract][Full Text] [Related]
33. Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression. Dong L; Zhou Q; Zhang Z; Zhu Y; Duan T; Feng Y J Obstet Gynaecol Res; 2012 Aug; 38(8):1077-85. PubMed ID: 22540333 [TBL] [Abstract][Full Text] [Related]
34. Isothiocyanate Iberin inhibits cell proliferation and induces cell apoptosis in the progression of ovarian cancer by mediating ROS accumulation and GPX1 expression. Gong TT; Guo Q; Li X; Zhang TN; Liu FH; He XH; Lin B; Wu QJ Biomed Pharmacother; 2021 Oct; 142():111533. PubMed ID: 34148735 [TBL] [Abstract][Full Text] [Related]
35. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines. Morgillo F; Sasso FC; Della Corte CM; Vitagliano D; D'Aiuto E; Troiani T; Martinelli E; De Vita F; Orditura M; De Palma R; Ciardiello F Clin Cancer Res; 2013 Jul; 19(13):3508-19. PubMed ID: 23695170 [TBL] [Abstract][Full Text] [Related]
36. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors. Sui M; Chen F; Chen Z; Fan W Int J Cancer; 2006 Aug; 119(3):712-7. PubMed ID: 16496381 [TBL] [Abstract][Full Text] [Related]
37. Folic acid-coupled nano-paclitaxel liposome reverses drug resistance in SKOV3/TAX ovarian cancer cells. Tong L; Chen W; Wu J; Li H Anticancer Drugs; 2014 Mar; 25(3):244-54. PubMed ID: 24275314 [TBL] [Abstract][Full Text] [Related]
38. [Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma]. Song Y; Shen K; Tang PP Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):761-4. PubMed ID: 18307904 [TBL] [Abstract][Full Text] [Related]
39. Acquisition of paclitaxel resistance via PI3K‑dependent epithelial‑mesenchymal transition in A2780 human ovarian cancer cells. Du F; Wu X; Liu Y; Wang T; Qi X; Mao Y; Jiang L; Zhu Y; Chen Y; Zhu R; Han X; Jin J; Ma X; Hua D Oncol Rep; 2013 Sep; 30(3):1113-8. PubMed ID: 23807572 [TBL] [Abstract][Full Text] [Related]
40. Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings. Tossetta G Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361682 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]